 |
CAMBRIDGE, Mass. and DAEJEON, South Korea, April 24, 2023 /PRNewswire/ -- BIORCHESTRA, a biotherapeutics company focused on rare and degenerative diseases within the Central Nervous System (CNS), today announced significant progress in its lead drug program – BMD-001. Leveraging a proprietary, IV-formulated brain-targeting RNAi Nanomedicine (BTRiNTM) platform that combines targeted cell delivery capabilities and proprietary RNA chemistries, BMD-001 has achieved significant milestones, including:
BIORCHESTRA's Scientific Founder, Chairman, and Chief Executive Officer, Dr. Branden Ryu, commented, "We are encouraged by these NHP findings, revealing that our IV formulation achieves consistent, sustained broad brain biodistribution and remarkable target knockdown across multiple measures. Today's results underpin the company's accelerated development of BMD-001 within our neurodegenerative disease franchise focused on Alzheimer's disease, Amyotrophic Lateral Sclerosis, and Parkinson's disease."
President & Chief Medical Officer, Dr. Louis St. L. O'Dea, commented, "Beyond achieving broad biodistribution in the brain, demonstrating significant target knockdown and related functional outcomes, our IV-formulated nanomedicine platform uniquely targets upstream epigenetic hallmarks associated with core downstream neurodegenerative disease pathologies. These include amyloid β plaques, neurofibrillary tangles, sustained activation of brain-resident macrophages and other immune cells that exacerbate amyloid and tau pathology." Dr. O'Dea added, "These results are notable given the challenges that have been encountered in providing meaningful therapeutic solutions for the rising number of patients, and their families, affected by neurodegenerative diseases." Dr. O'Dea concluded, "Based on my experience in RNA therapeutics at Moderna and Akcea/Ionis, I see these results as very promising ahead of early meetings with international regulatory agencies to discuss and gain agreement on our development strategies."
About Brain Targeting Ribonucleic Acid Interference (RNAi) Nanomedicine (BTRiNTM)
BTRiNTM targets an amino acid receptor in the blood-brain barrier shared by neurons, astrocytes, and microglia. In addition to significant functional outcomes in a non-human primate study of Alzheimer's disease, BTRiNTM has been leveraged with ASO and siRNA to validate the effective knockdown of a target implicated in Amyotrophic Lateral Sclerosis and Parkinson's disease. Ongoing company discovery and development research will leverage BTRiNTM for other underserved diseases, such as Glioblastoma multiforme, Lewy body dementia, Spinocerebellar ataxia type three, Frontotemporal dementia, Progressive supranuclear palsy. For more information, visit: www.biorchestra.com/science/our-scientific-approach
About BMD-001
Under development for efficient and effective IV administration targeting specific micro-RNA associated with neuroinflammation, mitochondrial dysfunction, neurodegeneration, and amyloid protein deposition in Alzheimer's disease, Amyotrophic Lateral Sclerosis, and Parkinson's disease. BMD-001 has successfully demonstrated the suppression of specific microRNA across rodent and non-human primate models, normalizing homeostatic processes, reducing amyloid and tau protein deposition, reducing neuroinflammation, and improving cognitive function.
About BIORCHESTRA
BIORCHESTRA is a biotherapeutics company focused on rare and neurodegenerative diseases within the Central Nervous System by leveraging its proprietary Brain Targeting RNAi Nanomedicine (BTRiNTM) platform. BTRiNTM combines targeted cell delivery capabilities and proprietary RNA chemistries to develop first and best-in-class therapeutics. The company has extensive research and development and GMP manufacturing capabilities in Daejeon, South Korea, and U.S. headquarters in Cambridge, Massachusetts, U.S.A. For more information, visit: www.biorchestra.com and follow us on Twitter @biorchestra and LinkedIn.
Safe Harbor Statement
This press release contains forward-looking statements. In addition, from time to time, our representatives or we may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including our financial performance and projections, revenue and earnings growth, and business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including our ability to change the company's direction, keep pace with new technology and evolving market needs, and the competitive environment of our business. These and other factors may cause our results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by our representatives or us may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether due to uncertainties and assumptions, the forward-looking events discussed in this press release, and other statements made from time to time by our representatives or us might not occur.
Investor Contact:
Skyline Corporate Communications Group, LLC
Scott Powell, President
One Rockefeller Plaza, 10th Floor
New York, NY 10020 USA
Office: (646) 893-5835 x2
Email: info@skylineccg.com
